Chordate Medical Holding AB (OSTO:CMH) FCF Margin %: -4,779.14% (As of Jun. 2025)


OSTO:CMH Chordate Medical Holding AB OSTO:CMH
46 GF Score
Price kr0.16
GF Value kr26.18
! 6 Warning Signs
View Full Analysis

What is Chordate Medical Holding AB FCF Margin %?

Chordate Medical Holding AB OSTO:CMH -60.40% 46 FCF Margin % is -4,779.14% as of Jun. 2025. GuruFocus rates OSTO:CMH with a GF Score™ of 46/100 and a GF Value™ of kr26.18. The stock has 6 warning signs investors should review.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Chordate Medical Holding AB's Free Cash Flow for the three months ended in Jun. 2025 was kr-7.79 Mil. Chordate Medical Holding AB's Revenue for the three months ended in Jun. 2025 was kr0.16 Mil. Therefore, Chordate Medical Holding AB's FCF Margin % for the quarter that ended in Jun. 2025 was -4,779.14%.

As of today, Chordate Medical Holding AB's current FCF Yield % is -5,965.28%.

The historical rank and industry rank for Chordate Medical Holding AB's FCF Margin % or its related term are showing as below:

OSTO:CMH' s FCF Margin % Range Over the Past 10 Years
Min: -23273.39   Med: -2682.12   Max: -1609.19
Current: -2595.17

During the past 10 years, the highest FCF Margin % of Chordate Medical Holding AB was -1609.19%. The lowest was -23273.39%. And the median was -2682.12%.

OSTO:CMH's FCF Margin % is not ranked
in the Medical Devices & Instruments industry.
Industry Median: -0.03 vs OSTO:CMH: -2595.17

Chordate Medical Holding AB FCF Margin % Related Terms

Chordate Medical Holding AB FCF Margin % Historical Data

* Premium members only.

The historical data trend for Chordate Medical Holding AB's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chordate Medical Holding AB FCF Margin % Chart

Chordate Medical Holding AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3,325.89 -2,453.17 -23,273.39 -2,911.07 -4,103.46

Chordate Medical Holding AB Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5,122.54 -4,782.43 -5,418.60 -1,047.32 -4,779.14

OSTO:CMH vs ABT, SYK, MDT: FCF Margin % Comparison

For the Medical Devices subindustry, Chordate Medical Holding AB's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chordate Medical Holding AB FCF Margin % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Chordate Medical Holding AB's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Chordate Medical Holding AB's FCF Margin % falls into.


OSTO:CMH
46GF Score
Chordate Medical Holding AB OSTO:CMH
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chordate Medical Holding AB FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Chordate Medical Holding AB's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-27.288/0.665
=-4,103.46 %

Chordate Medical Holding AB's FCF Margin for the quarter that ended in Jun. 2025 is calculated as

FCF Margin=Free Cash Flow (Q: Jun. 2025 )/Revenue (Q: Jun. 2025 )
=-7.79/0.163
=-4,779.14 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -4,779.14% mean?
Chordate Medical Holding AB (OSTO:CMH) has a FCF Margin % of -4,779.14% as of Jun. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Chordate Medical Holding AB and its competitors.
Is Chordate Medical Holding AB's FCF Margin % too high?
Chordate Medical Holding AB's current FCF Margin % is -4,779.14%. Overall, Chordate Medical Holding AB has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Chordate Medical Holding AB's FCF Margin % compare to ABT and SYK?
Chordate Medical Holding AB's FCF Margin % of -4,779.14% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Chordate Medical Holding AB and its competitors. Chordate Medical Holding AB's current FCF Margin % is -4,779.14%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chordate Medical Holding AB stock overvalued right now?
Chordate Medical Holding AB (OSTO:CMH) has a current FCF Margin % of -4,779.14%. The stock's GF Value™ is kr26.18, compared to a current price of kr0.16 — trading 99.4% below its estimated fair value. The current FCF Margin % is -4,779.14%. Chordate Medical Holding AB's overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Chordate Medical Holding AB (OSTO:CMH), the current FCF Margin % is -4,779.14% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chordate Medical Holding AB (OSTO:CMH) Overvalued in 2026?

Based on GuruFocus' analysis, Chordate Medical Holding AB stock appears to be undervalued. The current stock price of kr0.16 is trading 99.4% below its estimated GF Value™ of kr26.18.

Key valuation signals for OSTO:CMH:

  • FCF Margin %: -4,779.14%
  • GF Value™: kr26.18 vs. price of kr0.16 (99.4% below fair value)
  • GF Score™: 46/100 with 6 warning signs

No single metric tells the full story. See the OSTO:CMH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Chordate Medical Holding AB Business Description

Address Farogatan 33, 164 51 Kista, Kista, SWE, 164 40
Chordate Medical Holding AB is a medical technology company that has developed patented and CE-marked a new nerve-modulating treatment technology for chronic nasal congestion and chronic migraine. The company sells its products in Selected European markets, Israel, and Saudi Arabia. The company's product range is based on the CE-marked treatment units Chordate System S100 and S120 for rhinitis and S220 for migraine, registered for the indications of preventive treatment of chronic migraine and chronic rhinitis and use on patients. The company sells its product system, including treatments, through distributors to clinics and hospitals in its primary markets.
46GF Score

Get the complete analysis for OSTO:CMH

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.16
Price
kr26.18
GF Value